Literature DB >> 3484557

Specific immunosuppression by immunotoxins containing daunomycin.

E Diener, U E Diner, A Sinha, S Xie, R Vergidis.   

Abstract

Daunomycin, when conjugated with a targeting antigen by an acid-sensitive spacer, remains inactive at the intravascular pH of 7 but becomes active after cleavage within the acidic lysosomal environment of the target cell. This observation made it possible to construct cytocidal compounds that caused antigen-specific suppression of murine lymphocyte function. When daunomycin was coupled to the hapten conjugate of ovalbumin by an acid-sensitive cis-aconityl group, it caused hapten-specific impairment of immunocompetence in murine B lymphocytes in vitro and in vivo. Furthermore, the response by T lymphocytes to concanavalin A in vitro was selectively eliminated by a conjugate between daunomycin plus the acid-sensitive spacer and a monoclonal antibody specific for T cells.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3484557     DOI: 10.1126/science.3484557

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  19 in total

Review 1.  Monoclonal antibodies as magic bullets.

Authors:  F M Brodsky
Journal:  Pharm Res       Date:  1988-01       Impact factor: 4.200

2.  Antigen-specific drug-targeting used to manipulate an immune response in vivo.

Authors:  M M Abu-hadid; R B Bankert; G L Mayers
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

3.  Abrogation of antibody responses in rats to murine monoclonal antibody 791T/36 by treatment with daunomycin-cis-aconityl-791T/36 conjugates.

Authors:  L G Durrant; R A Robins; R A Marksman; M C Garnett; Y Ogunmuyiwa; R W Baldwin
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

Review 4.  Streptomycetes producing daunomycin and related compounds: do we know enough about them after 25 years?

Authors:  J Huk; M Blumauerova
Journal:  Folia Microbiol (Praha)       Date:  1989       Impact factor: 2.099

5.  Monoclonal antibody L6-daunomycin conjugates constructed to release free drug at the lower pH of tumor tissue.

Authors:  E Lavie; D L Hirschberg; G Schreiber; K Thor; L Hill; I Hellstrom; K E Hellstrom
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

Review 6.  Reversibly crosslinked nanocarriers for on-demand drug delivery in cancer treatment.

Authors:  Yu Shao; Wenzhe Huang; Changying Shi; Sean T Atkinson; Juntao Luo
Journal:  Ther Deliv       Date:  2012-12

7.  Cerebellar Purkinje cells incorporate immunoglobulins and immunotoxins in vitro: implications for human neurological disease and immunotherapeutics.

Authors:  Kenneth E Hill; Susan A Clawson; John W Rose; Noel G Carlson; John E Greenlee
Journal:  J Neuroinflammation       Date:  2009-10-29       Impact factor: 8.322

8.  Influence of Alternative Tubulin Inhibitors on the Potency of a Epirubicin-Immunochemotherapeutic Synthesized with an Ultra Violet Light-Activated Intermediate: Influence of incorporating an internal/integral disulfide bond structure and Alternative Tubulin/Microtubule Inhibitors on the Cytotoxic Anti-Neoplastic Potency of Epirubicin-(C3-amide)-Anti-HER2/neu Synthesized Utilizing a UV-Photoactivated Anthracycline Intermediate.

Authors:  C P Coyne; Toni Jones; Ryan Bear
Journal:  Cancer Clin Oncol       Date:  2012-11

9.  Synthesis of Gemcitabine-(C4-amide)-[anti-HER2/neu] Utilizing a UV-Photoactivated Gemcitabine Intermediate: Cytotoxic Anti-Neoplastic Activity against Chemotherapeutic-Resistant Mammary Adenocarcinoma SKBr-3.

Authors:  Cody P Coyne; Toni Jones; Ryan Bear
Journal:  J Cancer Ther       Date:  2012-10

10.  Effective drug-antibody targeting using a novel monoclonal antibody against the proliferative compartment of mammalian squamous carcinomas.

Authors:  L Ding; J Samuel; G D MacLean; A A Noujaim; E Diener; B M Longenecker
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.